Company: MDCXW
Filing Date: 2025-04-04
Form Type: POS AM
Source: 0001062993-25-007073
Chunk: 188

Company: Medicus Pharma Ltd.
Filing Date: 2025-04-04
Form: POS AM
Chunk 188
---
 FATCA withholding gross proceeds from the dispositions of stock. To prevent withholding on dividends, Non-U.S. Holders may be required to provide the Company (or its withholding agents) with applicable tax forms or other information. Non-U.S. Holders are urged to consult with their own tax advisors regarding the effect, if any, of FATCA to them based on their particular circumstances.

<div align='center'>-131-

PLAN OF DISTRIBUTION</div>

The prices at which the common shares covered by this prospectus may actually be disposed of may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale or at negotiated prices.

We will deliver the common shares offered hereby upon exercise of the Public Warrants. The full text of the Public Warrant contains instructions for exercise. In order to exercise the Public Warrants, a holder must deliver to us the information required in the full text of the Public Warrant along with payment for the exercise price of the common shares to be purchased. We will then deliver common shares in the manner described in the Public Warrant, a copy of which is filed as an exhibit to the registration statement of which this prospectus is a part.

Upon compliance by any holder with the instructions for exercise contained in the Public Warrant, we will, within the time allotted by the Public Warrant, issue to the holder common shares, free of a restrictive legend.

<div align='center'>-132-

EXPERTS AND LEGAL MATTERS</div>

No expert or counsel named in this prospectus as having prepared or certified any part of this prospectus or having given an opinion upon the validity of the securities being registered or upon other legal matters in connection with the registration or offering of the securities was employed on a contingency basis or had, or is to receive, in connection with the offering, a substantial interest, directly or indirectly, in the Company or its subsidiaries. Nor was any such person connected with the Company or any of its subsidiaries as a promoter, managing or principal underwriters, voting trustee, director, officer or employee.

The consolidated balance sheets of the Company and its subsidiaries as of December 31, 2024, and the related consolidated statements of operations and comprehensive loss, shareholders’ equity, and cash flows for the year then ended, have been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report which is included herein which report includes an explanatory paragraph